Paraquat Settlement Rejections: Why 900+ Plaintiffs Walked Away — and What the MDL Does Next

In September 2025, the parties in the federal Paraquat litigation signed a confidential master settlement agreement meant to resolve thousands of Parkinson's disease claims. One year later, more than 900 plaintiffs have reportedly rejected the deal — some firms report 80–100% opt-out rates — the court has ordered holdouts into limited discovery, and the threat of bellwether trials is back on the table.

  • Key facts:
  • A Master Settlement Agreement covering certain Paraquat claims was signed on September 3, 2025; its payment terms are confidential and there is no published payout grid.
  • A September 29, 2026 report revealed that more than 900 plaintiffs have rejected the settlement, with some law firms reporting rejection rates between 80% and 100%.
  • MDL 3004 sits in the Southern District of Illinois before Chief Judge Nancy Rosenstengel, with 6,602 actions pending and 8,495 filed in total as of October 1, 2026, plus more than 2,000 cases in Philadelphia state court.
  • In April 2026 the court appointed a special master to meet with holdout plaintiffs; in June 2026 it ordered plaintiffs who declined the settlement into limited discovery.
  • Syngenta is exiting paraquat production, Vermont has banned the herbicide, and California is phasing it out — even as the EPA maintains it has found no clear link from labeled uses.

The Settlement That Was Supposed to End the MDL

Paraquat is a herbicide — a chemical weed killer sold under names like Gramoxone — that thousands of farmworkers, applicators, and agricultural laborers say caused their Parkinson's disease. Their lawsuits were consolidated as In re: Paraquat Products Liability Litigation, MDL No. 3004, in the Southern District of Illinois, before Chief Judge Nancy Rosenstengel. An MDL (multidistrict litigation) gathers similar federal cases before one judge for pretrial proceedings while keeping each case individual.

After the court paused the litigation for over a year to let the parties negotiate, a Master Settlement Agreement was executed on September 3, 2025, with defendants Syngenta and Chevron. The terms were never made public: there is no published payout grid and no court-ordered compensation schedule. The deal was structured as an offer — each plaintiff could accept or decline — and the defendants needed enough acceptances to make the program work. That is where the plan ran into trouble.

Why 900+ Plaintiffs Said No

On October 2, 2026, reporting on the litigation revealed that hundreds of plaintiffs had rejected the tentative settlement. A September 29 report put the figure above 900 rejections — enough, analysts said, to leave the parties short of the participation threshold needed for the settlement to hold. Some law firms involved in the MDL reported rejection rates ranging from 80% to 100% among their clients. One analysis found that 183 of 217 plaintiffs in a tracked group said no.

Why would injured people turn down money? The sticking points have not been publicly disclosed by either side, which itself tells a story: in a confidential program, plaintiffs and their lawyers judge the offer against the strength of their individual cases. A farmer who personally mixed and sprayed paraquat for twenty years, with medical records and purchase logs, has a very different negotiating position than someone whose exposure is thinly documented. When the offer treats those cases alike, the strong cases walk away.

For clear explainer coverage of legal topics, see Problem Solved.

What the Court Did: Special Master and Limited Discovery

Judge Rosenstengel did not let the impasse sit. In April 2026, she appointed a special master — a court-appointed neutral — and ordered the master to meet with holdout plaintiffs, an attempt to resolve the resistance case by case. When that did not close the gap, the court escalated: in June 2026, plaintiffs who had declined their settlement offers were ordered into limited discovery, meaning they must now produce evidence of their exposure and diagnosis while the settlement effort continues in parallel.

The message is two-sided. To defendants, the court is saying the litigation will move forward with or without a deal. To holdouts, it is saying that rejecting the settlement means proving a case — exposure records, work history, medical documentation — under real deadlines. The parallel tracks raise the stakes for everyone.

Bellwether Trials: the Leverage Waiting in the Wings

A bellwether trial is an early test case, chosen to show both sides how juries respond to the evidence and arguments they will hear repeatedly. If the settlement collapses, the judge is expected to revive plans for a series of bellwether trials — a development both sides are watching closely.

The record so far gives each side something to cite. Plaintiffs point to a 2011 study in Environmental Health Perspectives of pesticide applicators and their spouses, which found about 2.5 times the odds of Parkinson's disease among people who had used paraquat. Defendants point to the EPA, which says it has found no clear link from labeled uses and notes that a 2020 update from the Agricultural Health Study reported no association between paraquat and Parkinson's disease. No court has ruled that paraquat causes Parkinson's disease. How the bellwether process would frame that dispute is exactly what makes trials the ultimate leverage.

Regulators Are Moving Even as Courts Deliberate

While the MDL works through its impasse, regulators have been shrinking paraquat's footprint. Syngenta is exiting paraquat production. Vermont has banned the herbicide outright. California is phasing it out. More than 30 countries ban paraquat, though it remains legal in the United States under tight restrictions — it is a restricted-use pesticide, and federal law requires private applicators to keep application records.

These regulatory moves do not decide the lawsuits, and defendants will argue they reflect politics rather than science. But they shape the narrative a jury would hear, and they explain why new cases are still being filed even as the MDL settlement is administered.

Who Benefits From This — and Who Does Not

Who benefits. (1) Plaintiffs with strong, well-documented exposure — personal spraying and mixing over years, with applicator licenses, spray logs, or purchase receipts — who gain leverage from the credible threat of trials and may negotiate better individual outcomes. (2) People who have not yet filed — the litigation is active, new cases are being accepted, and the settlement's troubles show the process is far from over. (3) Families who need clarity about what the "settlement" actually is — understanding that the 2025 agreement was an offer, not a final resolution, helps them make informed decisions with their lawyers.

Who does not benefit. (1) Claimants with thin or undocumented exposure — the June 2026 limited-discovery order means holdouts must now produce real evidence; claims built on "lived near a farm" without records face an uphill fight. (2) Plaintiffs hoping for a quick, certain payout — the opt-out fight has made the timeline longer and less predictable, not shorter. (3) Anyone relying on published settlement "averages" — the terms are confidential, and attorney analyses stress that any average mixes strong and weak claims, so no quoted figure predicts an individual outcome. Compensation varies widely by case, and most settlements are confidential.

Frequently Asked Questions

Why did so many plaintiffs reject the Paraquat settlement?

The specific sticking points have not been disclosed, but the pattern is familiar in mass torts: a confidential, one-size offer can undervalue strong cases with well-documented exposure. With some firms reporting 80–100% rejection rates, enough plaintiffs walked away to threaten the participation threshold the deal needed.

Who benefits from rejecting the settlement?

Plaintiffs with strong, documented exposure — years of personal mixing and spraying, with licenses, logs, and receipts — benefit most, because the credible threat of bellwether trials gives them leverage for better individual outcomes. Their lawyers can also prepare cases for the court-ordered discovery track.

Who does not benefit from opting out?

Claimants with thin or undocumented exposure do not benefit: the June 2026 order puts holdouts into limited discovery, where they must produce real evidence on deadlines. People who need a certain, fast payout also lose, because the fight has made the timeline longer and less predictable.

How do I start a Paraquat Parkinson's claim?

First, confirm a Parkinson's diagnosis from a physician, usually a neurologist. Second, assemble exposure evidence: applicator licenses, spray logs, purchase receipts, employment or payroll records, and photos of equipment or product labels. Third, request a free case review promptly — and see our eligibility guide for what firms look for.

Will there be bellwether trials?

Likely, if the settlement collapses. The judge paused the litigation for over a year to allow settlement talks; with 900+ rejections reported, she has already moved holdouts into limited discovery, and reviving early test trials is the expected next step if no deal is salvaged.

Can I still file a Paraquat lawsuit in 2026?

Yes — new cases are being accepted in the MDL and in state courts, subject to each state's statute of limitations. Because Parkinson's develops slowly, timing rules can be complex, so an early case review is the safest way to protect your deadline.

Disclaimer: This article provides general information about ongoing litigation, not legal or medical advice. Whether any claim is viable depends on its specific facts and the law of the applicable state. Compensation varies widely by case, and most settlements are confidential.

Watch on YouTube

Problem Solved on YouTube